Indiana should be able to breathe easy this week. It has very little chance of making it into the Big Ten championship game. On the other hand, Georgia's spot in the Southeastern Conference title game is so risky that if the Bulldogs lose they might have been better off sitting it out. Over the next two weeks, the warm familiarity of conference championship games, which began in 1992 thanks to the SEC, could run into the cold reality that comes with the first 12-team College Football Playoff. League title games give the nation's top contenders a chance to hang a banner and impress the CFP committee, but more than ever, the bragging rights come with the risk of a season-wrecking loss — even with an expanded field. “I just don’t think it’s a quality conversation,” Georgia coach Kirby Smart said last week, sticking with the time-honored cliche of looking no further than the next weekend's opponent. Those who want to have that talk, though, already know where Georgia stands. The Bulldogs (9-2) are ranked sixth in this week's AP Top 25 and projected somewhere near that in the next set of CFP rankings that come out Tuesday. They already have two losses and will have to beat No. 3 Texas or No. 20 Texas A & M in the SEC title game on Dec. 7 to avoid a third. How bad would a third loss hurt? The chairman of the selection committee insists that a team making a conference title game shouldn't count against it. What that really means won't be known until the games are played and the pairings come out on Dec. 8. "We're going to let the season play out," Michigan athletic director Warde Manuel said. “But I think teams who make that championship game, the committee looks at them and puts them in high esteem." All of which could be good news for Indiana in the unlikely event the Hoosiers find themselves playing for the Big Ten title. IU is coming off a flop in its first major test of the season, a 38-15 loss to Ohio State last weekend. After his team's first loss of the season, coach Curt Cignetti took offense to being asked whether the Hoosiers were still a playoff-caliber team. “Is that a serious question?” he asked. “I’m not even gonna answer that. The answer is so obvious.” What might hurt Indiana, which dropped five spots to No. 10 in the AP poll, would be another drubbing. The Hoosiers would be at least a two-touchdown underdog in a title-game matchup against top-ranked Oregon. The odds of that happening, however, are slim. It would take a Michigan upset over No. 2 Ohio State on Saturday, combined with a Maryland upset over No. 4 Penn State and, of course, an Indiana win over Purdue (1-10). Because this is the first year of the 12-team playoff, there's no perfect comparison to make. For instance, this is the first time Power Four conference champions are guaranteed a spot in the playoff. But 2017 provides a textbook example of how a team losing its conference title game suffered. That year, Alabama had one loss (to Auburn) and didn't play in the SEC title game, but made the four-team field ahead of Wisconsin, which was 12-1 after a loss to Ohio State in the Big Ten championship game. Ohio State didn't make it either — two losses didn't get teams into a four-team field. Neither did undefeated UCF. Saturday's results made things a little more clear for the rest of the conferences: — In the Big 12, winning the title game will probably be the only way for Arizona State (9-2), BYU (9-2), Iowa State (9-2), Colorado (8-3) or anyone else to earn a spot in the 12-team playoff. None are ranked higher than 14th in the AP poll. — The Atlantic Coast Conference could get multiple bids. Miami (10-1), SMU (10-1) and Clemson (9-2) all finished in the top 12 of this week's AP poll. They were cheering the loudest when both Alabama and Ole Miss suffered their third losses of the season. — The Mountain West would be a one-bid conference, but that's only a sure thing if Boise State wins. A loss by the Broncos could open the CFP for Tulane or Army of the American Athletic. Both the MWC and AAC title games take place at 8 p.m. on Dec. 6. — Where the committee places Alabama and Ole Miss on Tuesday will be an indicator of what it thinks of teams with three losses that played very strong schedules. — It could also set the stakes for Georgia, which faces the prospect of loss No. 3 in the Dec. 7 title game, assuming the Bulldogs beat rival Georgia Tech this week. — Clemson has been steadily climbing. Its 34-3 loss to Georgia came on Aug. 31. Is it ancient history to the committee, though? — Indiana's status as a playoff team — in, out, nervous? — will become apparent. The Ohio State game was Indiana's first against a top-flight opponent. Then again, it is the Hoosiers' only loss and their weak Big Ten schedule is not their fault. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-footballslot game rules 。

It’s dead right to be up in armbands against woke Football Association

PLEASANTON, Calif. , Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023 . The injunction, which the Court said it will enter in January 2025 , is expected to prohibit Bruker from making, using, selling or offering to sell in the United States its GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection. At the request of 10x Genomics, the injunction will not block ongoing research by researchers who installed a GeoMx instrument prior to November 18, 2023 . Such customers can continue to purchase GeoMx reagents for use with existing GeoMx instruments for purposes of continuing their ongoing research. The Court found that making such an exception for ongoing research strikes a "workable balance between protecting the patentee's rights and protecting the public from the injunction's adverse effects." In addition, the Court affirmed the $31 million damages awarded by the November 2023 jury verdict, as well as supplemental damages and interest that will be added to the total damages when final judgment is entered. "Today's decision helps to safeguard our decade-long investment in innovation and ensures we can continue to develop groundbreaking technologies that help our customers revolutionize science," said Eric Whitaker , Chief Legal Officer at 10x Genomics. "10x exists to fuel scientific progress – not stifle it – and that is why we've done our utmost to ensure this injunction was structured to protect both our intellectual property and existing GeoMx customers' ongoing research." The Court recognized the harm NanoString's infringing conduct caused 10x when it wrote in its ruling, "Having been careful not to license its technology, 10x suffers when it proclaims itself as an innovator in spatial genomics but a competitor is using the same innovative, patented technology." Today's Court decision follows a November 2023 jury verdict that found that NanoString's GeoMx products willfully infringed seven patents exclusively licensed to 10x Genomics by Prognosys. During the trial, the jury heard testimony from the sole inventor of the patents, Illumina co-founder Mark Chee , and NanoString CEO Brad Gray and NanoString CSO Joe Beechem. After hearing all of the evidence, the jury determined that all seven patents had been infringed by NanoString, that each patent was valid, that NanoString willfully infringed those patents and that monetary damages were owed to 10x for the infringement of all seven patents. In affirming the jury's finding that NanoString willfully infringed, the Court relied on the evidence showing that NanoString knew or was willfully blind that its acts would cause infringement of 10x's rights. The asserted patents in Case No. 21-cv-653-MFK include (a) U.S. Patent No. 10,472,669; (b) U.S. Patent No. 10,961,566; (c) U.S. Patent No. 10,983,113; (d) U.S. Patent No. 10,996,219; (e) U.S. Patent No. 11,001,878; (f) U.S. Patent No. 11,008,607 and (g) U.S. Patent No. 11,293,917. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter) . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation and remedies as well as possible outcomes of litigation. These forward-looking statements do not reflect that our success will depend on our ability to obtain, maintain and protect our intellectual property rights, intellectual property litigation could be expensive, time-consuming, unsuccessful and could interfere with our ability to develop, manufacture and commercialize our products or technologies, litigation outcomes are unpredictable or there may be changes in our litigation strategy. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2023 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, our website ( www.10xgenomics.com ), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Contacts Investors: investors@10xgenomics.com Media: media@10xgenomics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/us-district-court-awards-10x-genomics-permanent-injunction-in-patent-infringement-lawsuit-against-bruker-corporations-geomx-products-302338627.html SOURCE 10x Genomics, Inc.

BOGOTÁ, Colombia (AP) — One of Colombia’s legendary drug lords and a key operator of the Medellin cartel has been deported back to the South American country, after serving 25 years of a 30-year prison sentence in the United States. A short while later, Fabio Ochoa was again a free man. Ochoa arrived in Bogota’s El Dorado airport on a deportation flight on Monday, wearing a grey sweatshirt and carrying his personal belongings in a plastic bag. After stepping out of the plane, the former cartel boss was met by immigration officials in bullet proof vests. There were no police on site to detain him. Colombia’s national immigration agency promptly posted a brief statement on the social media platform X, saying Ochoa was “freed so that he could join his family” after immigration officials took his fingerprints and confirmed through a database that he is not wanted by Colombian authorities. Ochoa, 67, and his older brothers amassed a fortune when cocaine started flooding the U.S. in the late 1970s and early 1980s, according to U.S. authorities, to the point that in 1987 they were included in the Forbes Magazine’s list of billionaires. Living in Miami, Ochoa ran a distribution center for the cocaine cartel once headed by Pablo Escobar . Escobar died in a shootout with authorities in Medellin in 1993. Ochoa was first indicted in the U.S. for his alleged role in the 1986 killing of Barry Seal, an American pilot who flew cocaine flights for the Medellin cartel, but became an informant for the Drug Enforcement Administration. Along with his two older brothers, Juan David and Jorge Luis, Ochoa turned himself in to Colombian authorities in the early 1990s under a deal in which they avoided being extradited to the U.S. The three brothers were released from prison in 1996, but Ochoa was arrested again three years later for drug trafficking and was extradited to the U.S. in 2001 in response to an indictment in Miami naming him and more than 40 people as part of a drug smuggling conspiracy. He was the only suspect in that group who opted to go to trial, resulting in his conviction and a 30-year sentence. The other defendants got much lighter prison terms because most of them cooperated with the government. Ochoa’s name has faded from popular memory as Mexican drug traffickers take center stage in the global drug trade. But the former member of the Medellin cartel was recently depicted in the Netflix series Griselda, where he first fights the plucky businesswoman Griselda Blanco for control of Miami’s cocaine market, and then makes an alliance with the drug trafficker, played by Sofia Vergara. Ochoa is also depicted in the Netflix series Narcos, as the youngest son of an elite Medellin family that is into ranching and horse breeding and cuts a sharp contrast with Escobar, who came from more humble roots. Richard Gregorie, a retired assistant U.S. attorney who was on the prosecution team that convicted Ochoa, said authorities were never able to seize all of the Ochoa family’s illicit drug proceeds and he expects that the former mafia boss will have a welcome return home. “He won’t be retiring a poor man, that’s for sure,” Gregorie told The Associated Press earlier this month.

MENLO PARK, Calif. , Dec. 23, 2024 /PRNewswire/ -- BillionToOne, a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that they will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA , on January 14, 2025 . BillionToOne marks a transformative year of achievements as it looks toward 2025. The company closed an oversubscribed, upsized Series D funding round led by Premji Invest in June, and was recently recognized as the Biotech Breakthrough Awards' Diagnostics Company of the Year. More than 500,000 patients have received BillionToOne tests to date, and the company has grown from $0M to $150M+ in annual recurring revenue over the past five years. This will be BillionToOne's second year in attendance at the J.P. Morgan Healthcare Conference, and the company will present on the topic of "Redefining Molecular Diagnostics with Single-Molecule Precision." Presentation details are as follows: Location: Mission Bay (32nd Floor) at The Westin Date: Tuesday, January 14, 2025 Time: 2:30-2:55 pm PT A webcast and presentation materials will be available on BillionToOne's website: https://billiontoone.com/event/jpm-2025-43rd-annual-healthcare-conference/ About BillionToOne Headquartered in Menlo Park, California , BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for everyone. The company's patented Quantitative Counting TechnologyTM (QCTTM) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, please visit www.billiontoone.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/billiontoone-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302338634.html SOURCE BillionToOne